LRRK2 and Parkinson disease: Rare GoF mutations in LRRK2 with high and moderate penetrance and common regulatory variants affecting LRRK2 gene expression significantly increase Parkinson’s disease risk [30], suggesting that inhibiting LRRK2 kinase activity may be therapeutic.